Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.55 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399440 | 1.00 | MMP2 (0.55) | MMP2DPP4ANPEPCTSLCTSB | |
| Danegaptide SCHEMBL20547963 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL25694359 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL2521817 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL29094836 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL2399763 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL2399760 | 0.91 | MMP2 (0.56) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL2399462 | 0.90 | MMP2 (0.55) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL4040777 | 0.90 | MMP2 (0.55) | MMP2ANPEPCTSLCTSBCTSK | |
| Danegaptide SCHEMBL4040780 | 0.90 | MMP2 (0.55) | MMP2ANPEPCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386539-B1 | 4-Aminoproline derivatives useful as lysine mimetics | ZEALAND PHARMA AS (DK) | 2016-07-20 | — | — | EP | claimed |
| EP-1966130-B1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA AS (DK) | 2013-12-11 | — | — | EP | claimed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | claimed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | claimed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-1966130-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S (DK) | 2008-09-10 | — | — | EP | claimed |
| WO-2007078990-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2007-07-12 | — | — | WO | claimed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | claimed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1966130-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007078990-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885DPP4 370/4885ANPEP 491/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885DPP4 370/4885ANPEP 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.